Sanofi To Close Dijon Facility

21 November 1994

Sanofi is to close the Sterling-Midy-Industrie drug research center near Dijon, France, sometime in 1995. The closure is the result of the purchase by Sanofi of Sterling's pharmaceutical business. Many of the staff are likely to be transferred to one of Sanofi's two research centers at Montpelier and Toulouse. Meantime, Sanofi is continuing its divestment policy with an agreement to sell its Perry Ellis line of fragrances to the US company Parlux Fragrances. The Perry Ellis brand has sales of around $19 million per year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight